AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
WALTHAM, Mass., Feb. 28, 2018 -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced its support for the patient and research communities in recognition of Rare Disease Day 2018.
“At Chiasma, we are focused on improving the lives of patients who face challenges associated with existing treatments for their rare and debilitating diseases,” said Mark Fitzpatrick, president and CEO of Chiasma. “The theme for Rare Disease Day 2018 is ‘research’ – and for good reason. Last year, rare or orphan disease treatments accounted for nearly 40% of all new drugs approved by the FDA -- all to the benefit of the patients and their families who desperately need treatments. For this reason, we also pay tribute to the patient community, which makes our drug development efforts so meaningful. We strongly believe in our own mission, to enhance the lives of adult patients living with acromegaly, and we join with policy makers, researchers, companies and healthcare professionals in the drive to increasingly and more effectively involve patients in rare disease research.”
Rare Disease Day takes place on the last day of February each year. The main objective is to raise awareness among the general public and decision-makers about rare diseases and their impact on patients' lives. For more information about Rare Disease Day, please visit www.rarediseaseday.org.
About Chiasma
Chiasma is focused on improving the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. The Company recently initiated CHIASMA OPTIMAL, its third Phase 3 clinical trial for its octreotide capsules product candidate, conditionally trade-named MYCAPSSA®, for the maintenance therapy of adult patients with acromegaly in whom prior treatment with somatostatin analogs has been shown to be effective and tolerated following SPA agreement with the FDA on the design of the trial. Chiasma is headquartered in Waltham, MA with a wholly owned subsidiary in Israel. MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma. For more information, please visit the Company’s website at www.chiasma.com.
Contact:
Andrew Blazier
Sharon Merrill Associates
(617) 542-5300
[email protected]
